Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Chronic kidney disease is an important health issue associated with increased morbidity, mortality, and health care costs. Chronic kidney disease is defined as greater than 3 months of decreased kidney function, identified by a reduced estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 or by blood or urine markers of kidney damage regardless of eGFR.1 Using this definition, about which there remains some controversy, more than 14% of the US population has CKD and 6% have stage 3 CKD or higher.2,3 Stage 3 CKD confers a greater risk of CKD-related complications and progression to end-stage renal disease (ESRD).3 Because CKD has a long asymptomatic phase, there are acceptable screening tests, and the health consequences associated with the disease are high, it is a disease that is amenable to screening. Screening could also be beneficial because only 10% of people with CKD know they have the disease, and treatments exist that delay the progression of CKD.4
Saunders MR, Cifu A, Vela M. Screening for Chronic Kidney Disease. JAMA. 2015;314(6):615–616. doi:10.1001/jama.2015.9425
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: